Rexin G

<p>Rexin G is a tumor-targeted <a href="/facts/Genetics/bu8wne0A">genetic</a> medication for cancer. Its primary mechanism is a retrovector bearing a cytocidal <a href="/facts/Cyclin/XtodJmQa">cyclin</a> <a href="/facts/G1_phase/92lq1LdT">G1</a> construct, which is a form of targeted <a href="/facts/Gene_therapy/CaxRLfKM">gene therapy</a> vector used to get a fast track <a href="/facts/Orphan_drug/96judAS6">orphan drug</a> priority for multiple cancer indications within the <a href="/facts/United_States/P0sCdLe5">United States</a>. After phase one and two clinical trials, the drug has been shown to effectively shrink <a href="/facts/Metastatic_tumor/4dadbm6z">metastatic tumors</a> and triple the survival times of chemotherapy-resistant <a href="/facts/Pancreatic_cancer/6h9GIInW">pancreatic cancers</a>. Recent studies have also confirmed the overall safety of the Rexin G drug and have shown that Rexin-G <a href="/facts/Monotherapy/rtvKq6Pq">monotherapy</a>, at the recommended dose levels, exhibits significant <a href="/facts/Anti-tumor/fWTLbaUT">anti-tumor</a> activity and increases both overall survival time and the survival rates in the majority of patients.
</p>

Rexin G open-in-new

Rexin G